Concentrations of the Stress Hormone Copeptin Increase upon Hypoglycaemia in Patients with Type 1 Diabetes Dependent of Hypoglycaemia Awareness

被引:12
|
作者
Seelig, Eleonora [1 ]
Bilz, Stefan [2 ]
Keller, Ulrich [1 ]
Meienberg, Fabian [1 ]
Christ-Crain, Mirjam [1 ]
机构
[1] Univ Basel Hosp, Dept Diabetol Endocrinol & Metab, CH-4031 Basel, Switzerland
[2] Kantonsspital, Dept Endocrinol, St Gallen, Switzerland
来源
PLOS ONE | 2013年 / 8卷 / 08期
关键词
INSULIN-INDUCED HYPOGLYCEMIA; ARGININE-VASOPRESSIN; STABLE PEPTIDE; PRECURSOR; PLASMA; SECRETION; RESPONSES; FAILURE; ASSAY;
D O I
10.1371/journal.pone.0072876
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: Copeptin, a marker for stress mirroring vasopressin concentrations, has been shown to increase upon insulin-induced hypoglycaemia in patients after transsphenoidal surgery of pituitary adenomas. Patients with type 1 diabetes mellitus are prone to hypoglycaemia, but no data about copeptin levels upon hypoglycaemia are available. Furthermore, the perception of hypoglycaemia can vary from total unawareness to disabling episodes. The aim of this study was to investigate whether copeptin increases upon hypoglycaemia in patients with type 1 diabetes mellitus and is associated with the degree of hypoglycaemia awareness. Materials and Methods: In this prospective observational study, 17 patients with type 1 diabetes underwent a standardized insulin infusion test. Blood sampling for glucose and copeptin was performed at baseline and after 60 minutes (min). To assess hypoglycaemia associated symptoms the Mood and Symptom Questionnaire (MSQ) was conducted at baseline and after 60 min. Results: During insulin infusion, blood glucose decreased from 5.1 (SD +/- 0.2) to 3.0 (+/- 0.5) mmol/L at 60 min (p<0.001). Copeptin concentrations increased from 3.2 (+/- 1.7) to 3.8 (+/- 1.9) pmol/L (p = 0.03). Mood and Symptoms Questionnaire scores increased from 14 (+/- 3.0) to 18 (+/- 5.8), (p = 0.006). Patients with good hypoglycaemia awareness had an increase in copeptin from 3.0 (+/- 1.8) to 4.2 (+/- 2.4) pmol/L (p = 0.03) in contrast to patients more unaware of hypoglycaemia who only showed an increase in copeptin from 3.3 (+/- 1.6) to 3.6 (+/- 1.4) pmol/L (p = 0.4). There was a trend to a larger copeptin increase in patients aware of hypoglycemia compared to patients unaware of hypoglycemia (p = 0.074). Conclusion: Copeptin increases in patients with type 1 diabetes upon insulin induced hypoglycaemia. Interestingly, the copeptin increase seems associated with the degree of hypoglycaemia awareness. This hypothesis warrants further verification.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] A parallel increase in placental oxidative stress and antioxidant defenses occurs in pre-gestational type 1 but not gestational diabetes
    Araujo, J. R.
    Ramalho, C.
    Correia-Branco, A.
    Faria, A.
    Ferraz, T.
    Keating, E.
    Martel, F.
    PLACENTA, 2013, 34 (11) : 1095 - 1098
  • [42] Influence of Chlorhexidine and Cetylpyridine on Periodontal Status and Indicators of Oxidative Stress in Patients with Type 1 Diabetes
    Lipski, Jakub
    Duda-Sobczak, Anna
    Napierala, Marta
    Florek, Ewa
    Zozulinska-Ziolkiewicz, Dorota
    Wyganowska-Swiatkowska, Marzena
    ANTIOXIDANTS, 2021, 10 (11)
  • [43] Vitamin E Supplementation May Ameliorate Oxidative Stress in Type 1 Diabetes Mellitus Patients
    Gupta, Shallu
    Sharma, Tarun Kumar
    Kaushik, G. G.
    Shekhawat, V. P. S.
    CLINICAL LABORATORY, 2011, 57 (5-6) : 379 - 386
  • [44] A Single Bout of High-Intensity Interval Training Reduces Awareness of Subsequent Hypoglycemia in Patients With Type 1 Diabetes
    Rooijackers, Hanne M.
    Wiegers, Evita C.
    van der Graaf, Marinette
    Thijssen, Dick H.
    Kessels, Roy P. C.
    Tack, Cees J.
    de Galan, Bastiaan E.
    DIABETES, 2017, 66 (07) : 1990 - 1998
  • [45] The administration of an active vitamin D3 analogue reduced the serum concentrations of 1-84 and truncated parathyroid hormone in pseudohypoparathyroidism type Ib patients
    Ishii, Akira
    Imanishi, Yasuo
    Kurajoh, Masafumi
    Nagata, Yuki
    Kobayashi, Keisuke
    Miki, Takami
    Inaba, Masaaki
    Nishizawa, Yoshiki
    ENDOCRINE JOURNAL, 2010, 57 (07) : 609 - 614
  • [46] Serum Concentrations of Markers of TNFα and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes
    Niewczas, Monika A.
    Ficociello, Linda H.
    Johnson, Amanda C.
    Walker, William
    Rosolowsky, Elizabeth T.
    Roshan, Bijan
    Warram, James H.
    Krolewski, Andrzej S.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (01): : 62 - 70
  • [47] Effect of Exercise-Induced Lactate Elevation on Brain Lactate Levels During Hypoglycemia in Patients With Type 1 Diabetes and Impaired Awareness of Hypoglycemia
    Wiegers, Evita C.
    Rooijackers, Hanne M.
    Tack, Cees J.
    Groenewoud, Hans J. M. M.
    Heerschap, Arend
    de Galan, Bastiaan E.
    van der Graaf, Marinette
    DIABETES, 2017, 66 (12) : 3105 - 3110
  • [48] Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls
    Zibar, Karin
    Cuca, Jadranka Knezevic
    Blaslov, Kristina
    Bulum, Tomislav
    Smircic-Duvnjak, Lea
    ANNALS OF CLINICAL BIOCHEMISTRY, 2015, 52 (02) : 220 - 225
  • [49] Dietary Fat Acutely Increases Glucose Concentrations and Insulin Requirements in Patients With Type 1 Diabetes Implications for carbohydrate-based bolus dose calculation and intensive diabetes management
    Wolpert, Howard A.
    Atakov-Castillo, Astrid
    Smith, Stephanie A.
    Steil, Garry M.
    DIABETES CARE, 2013, 36 (04) : 810 - 816
  • [50] Combined intake of caffeine and low-dose glucose to reduce exercise-related hypoglycaemia in individuals with type 1 diabetes on ultra-long-acting insulin degludec: A randomized, controlled, double-blind, cross-over trial
    Kuhne, Tobias
    Wallace, Esme
    Herzig, David
    Helleputte, Simon
    Scott, Sam
    Pickles, Jordan
    Melmer, Andreas
    Stettler, Christoph
    DIABETES OBESITY & METABOLISM, 2024, 26 (07) : 2645 - 2651